In addition to being an established complicating factor for myocardial infarction (MI), recent studies have revealed that atrial fibrillation (AF) increased risk of MI. This study is to evaluate the risk of MI associated with AF in a nationwide population based cohort. We examine the association between AF and incident MI in 497,366 adults from the Korean National Health Insurance Service database, who were free of AF and MI at baseline. AF group (n = 3,295) was compared with propensity matched no-AF group (n = 13,159). Over 4.2 years of follow up, 137 MI events occurred. AF was associated with 3-fold increased risk of MI (HR, 3.1; 95% CI, 2.22-4.37) in both men (HR, 2.91; 95% CI 1.91-4.45) and women (HR, 3.52; 95% CI 2.01-6.17). The risk of AF-associated MI was higher in patients free of hypertension, diabetes, ischemic stroke, and dyslipidemia at baseline. The cumulative incidence of AF-associated MI was lower in patients on anticoagulant and statin therapies. Our finding suggests that AF complications beyond stoke should extend to total mortality to include MI.
Statistical analysis. Data were presented as mean ± SD for normally distributed continuous variables and as proportions for categorical variables. Age-adjusted incidence rate of MI per 1000 person-years in patients with and without AF was calculated in the propensity matched population and in the sex subgroup. Person-time for the incidence rate in the AF group was calculated from AF diagnosis to the occurrence of MI or censoring. In the no-AF group, person-time was calculated from baseline to MI occurrence or censoring. Cumulative incidence of MI was plotted using a Kaplan-Meier method, with statistical significance examined using log-rank test by AF status. The risk of MI was assessed using Cox regression analysis. Statistical analysis was performed using SPSS 21.0 statistical software (SPSS Inc., Chicago, IL, USA). All p-values were two tailed, and values less than 0.05 were considered statistically significant.
Results
Baseline characteristics. The mean age of matched patients was 63 years (range, 19-98 years) and 58% of the patients were male. Table 1 shows the baseline characteristics of the study population stratified by AF status. In the full pre-match cohort, patients with AF were older, had a higher body mass index, a higher prevalence of heart failure (HF), hypertension, diabetes, CKD or ESRD, dyslipidemia, ischemic stroke, PAOD, and COPD (all P < 0.001). Mean CHA 2 DS 2 -VASc score was 2.6 ± 1.9 in the AF group and 1.2 ± 1.3 in the no-AF group (P < 0.001). Covariates with significant imbalances in the pre-matched cohort which were well balanced after propensity matching are displayed in Table 1 . Absolute standardized differences in all measured covariates were less than 5%, suggesting substantial covariate balance across the groups ( Supplementary Fig. S1 ).
Aspirin, anticoagulants, statin, digoxin, beta blocking agent (BB), and calcium channel blocker (CCB) were more frequently prescribed in the AF group than in the no-AF group; aspirin (50.3% vs. 27.5%, P < 0.001), anticoagulant (20.9% vs. 0.3%, P < 0.001), statin (38.2% vs. 28.5%, P < 0.001), digoxin (13.4% vs. 0.9%, P < 0.001), BB (43.1% vs.16.1%, P < 0.001), and CCB (11.4% vs. 2.5%, P < 0.001).
AF and the risk of MI. Over 4.2 years of follow up, 137 incident MI events occurred. Figure 2 shows the unadjusted cumulative incidence of MI stratified by baseline AF status in the entire cohort ( Fig. 2a ) and the matched cohort ( Fig. 2b ). Patients with AF had a higher incidence of MI than those without AF in both the entire cohort and the matched cohort (log rank p < 0.001 for both cohorts).
The age-adjusted incidence rate of MI among participants was higher in those with AF than in those without AF (4.42 vs 1.42 per 1000 person-years), with an incidence rate ratio (IRR) of 3.12 [95% CI, 2.23-4.36]. In a sex stratified analysis, the higher age-adjusted MI IRRs by AF status was observed in women (IRR, 3.65; 95% CI, 2.09-6.38) compared with men (IRR, 2.88; 95% CI, 1.89-4.39) ( Fig. 3 ). In a Cox proportional hazards model of the matched cohort, AF [Hazard ratio (HR), 3.12; 95% CI, 2.23-4.37, p < 0.001] was an independent risk factor for MI. Other risk factors were hypertension (HR, 1.87; 95% CI, 1.30-2.69, p < 0.001), diabetes (HR, 1.79; 95% CI, 1.28-2.51, p < 0.001), HF (HR, 2.04; 95% CI, 1.32-3.14, p = 0.003), CKD or ESRD (HR, 2.70; 95% CI, 1.90-3.85, p < 0.001) and dyslipidemia (HR, 1.45; 95% CI, 1.04-2.03, p = 0.031) ( Table 2 ). Age-adjusted incidence rate and incidence rate ratios of myocardial infarction by atrial fibrillation status. Incidence rate per 1,000 person-years. *Age adjusted incidence rate and incidence rate ratios were based on the average of the cohort. Association of AF with MI in subgroups. The associations of AF with MI among various subgroups of patients are displayed in Fig. 4 . The risk of hospitalization or death due to MI was significantly higher in the AF group than in the no-AF group, regardless of age (p for interaction = 0.1), sex (p for interaction = 0.6), comorbidities with HF (p for interaction = 0.11), and CKD or ESRD (p for interaction = 0.56) at baseline. On the other hand, we found that the risk of AF associated incident MI was higher in patients free of hypertension 
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Risk of MI in association with medications in AF patients.
Medications analyzed in this study were aspirin, anticoagulants, statin, digoxin, BB and CCB. Anticoagulants included in the analysis were warfarin, direct thrombin inhibitor and factor Xa inhibitors. Pharmacological treatment was ascertained when there were at least 90 days or more prescriptions were prescribed after the incident diagnosis of AF. Figure 5 shows the effect of each medication on the occurrence of MI in AF patients. Anticoagulants were prescribed in 688 of the 3,295 AF patients without gender difference in prescription rate (men, 21.1% vs. women, 20.6%, p = 0.76). AF associated incident MI occurred less in patients on anticoagulant (0.6% vs. 2.1%, p = 0.004). Statins were prescribed in 1,259 of the 3,295 AF patients and prescription rate was higher in women than in men (men, 34.1% vs. women, 43.9%, p < 0.001). AF associated incident MI was less in patients on statin therapy (1.3% vs. 2.2%, p = 0.05). Cumulative incidence of MI was lower in patients who were taking an anticoagulant (Fig. 5b , p = 0.004) and statin (Fig. 5c , p = 0.039). Aspirin users showed a similar trend, which did not reach statistical significance ( Fig. 5a , p = 0.058). The most commonly prescribed rate control agent was BB, followed by digoxin and CCB. AF-associated MI events did not differ between patients who were taking digoxin (Fig. 5d ), BB (Fig. 5e ), and CCB ( Fig. 5f ) and those who were not taking these medications. Overall death, regardless of the mode of death, occurred more often in patients with MI than in those without MI during the follow up period (35.8% vs 4.6%, p < 0.001).
Discussion
In this study from NHIS, our principal findings are as follows: (1) AF was significantly associated with increased risk of incident MI. (2) Association between AF and the risk of MI did not differ by sex. (3) The risk of AF associated incident MI was higher in patients free of hypertension, diabetes, ischemic stroke, and dyslipidemia. (4) The incidence of AF associated incident MI was lower in patients on anticoagulant and statin therapies.
In this study, AF was associated with 3-fold increased risk of MI, even after the risk factors and potential confounders for MI were included in the matching. These findings were in accordance with the recently reported several studies which showed AF as an independent risk factor for MI 6, 7, 14, 15 . Contrary to recent studies which showed gender difference in the association between AF and MI 6,7,15 , it were not observed in this study. Previously, it was reported that women were less likely to receive warfarin than men 16, 17 and this may be the possible explanation for gender difference of MI 14 . However, in our study, use of anticoagulant did not differ between sex and this, in part, may contribute to the similar risk of MI between men and women.
Notably, we confirmed that the risk of MI was significantly higher in patients with AF free of overt cardiovascular disease than in subjects without AF. Previous study from Olmsted County revealed that lone AF had a comparable risk of embolic events and mortality to the general population 18, 19 . In contrast, recent studies showed that patients with AF without cardiovascular co-morbidities had an increased risk of cardiovascular events and mortality 15, 20 . These interactions suggest that shared underlying risk factors are not the only mechanisms explaining the association between AF and MI. There are plausible explanations for why AF patients with less co-morbidity were predisposed to MI. In patients with established risk factors for MI, AF may contribute less to the occurrence to MI, compared with those who were previously healthy. In our study, anticoagulants showed beneficial effect against AF associated incident MI. Accordingly, embolic events to coronary arteries are another possible explanation. Statin use, and also, is higher in patients with cardiovascular diseases, which may decrease the incident MI. Further study is needed in this regard.
In this analysis stratified by medications after AF diagnosis, the risk of incident MI was less in anticoagulant users. Previously, it was reported that warfarin might have a protective effect against MI 21 . Prevention of thrombus formation with anticoagulation, in part, might be an explanation. In our study, the anticoagulants analyzed were direct thrombin inhibitor, factor Xa inhibitors, as well as warfarin, and whether the new oral anticoagulants could have a role in preventing MI in the setting of AF needs to be further investigated.
Clinical trials have already demonstrated a clear beneficial effect of statin for prevention of ischemic heart disease 22, 23 . In accordance with these studies, this study revealed that the risk of AF associated incident MI was less in statin users than in non-users. In a study, association between AF and inflammation has been reported 24 . The role of inflammation in MI has already been established 25 . Anti-inflammatory and anti-thrombotic activities of statin may reduce the risk of AF associated incident MI. Type 2 MI can occur due to poorly controlled ventricular response in AF patients 26 . The rate control strategy in AF patients is expected to reduce the occurrence of type 2 MI, by reducing the oxygen demand and by increasing the diastolic filling time of coronary arteries. However, the result of this study was not in accordance with this common belief, suggesting that type 2 MI is less likely to be the main mechanism by which AF leads to MI.
Considering MI as a known risk factor for AF 27 , this result suggests a bidirectional relationship between AF and MI. However, the pathophysiology of AF associated incident MI is complex and incompletely understood. Further research to determine the underlying mechanism with the association of AF and MI is warranted. The prevalence of AF doubles with each additional decade of life 28 . With an increasing older population, the occurrence of AF itself and AF-associated morbidity and mortality is expected to increase as well. From a preventive perspective, the notion should suggest that AF potentiates the risk of MI.
Limitations
There are several limitations to this study. Although we ascertained AF cases with ECGs as well as ICD codes, it is possible that paroxysmal or asymptomatic AF cases were not detected. Also, we could not analyze paroxysmal, persistent and permanent AF separately. Second, because MI cases were identified by ICD-10 code, data for cardiac markers, ECGs, and coronary angiography were not available, which could have provided further information about the type of MI 26 . We could not analyze the association of AF with different types of MI. Third, even though the NHIS recommends biennial health check-up to all health insurance subscribers, it is not compulsory and there is a possibility that healthier and more educated subjects could have participated in this study. Fourth, potentially uncontrolled covariates may exist because comorbidities included in propensity matching are the data from baseline examination. They may be absent at baseline, but may have developed during the follow-up. Fifth, similar to other studies, considerable confounders may remain although propensity-score matching was well balanced. Despite the limitations, this study is the nation-wide population based observational studies providing the further evidence for a link between AF and MI, and the effects of medications on the occurrence of AF related incident MI.
